Fezolinetant (formerly ESN364; ESN-364) is novel, potent and orally bioavailable antagonist of the Neurokinin-3 (NK-3) receptor being developed for the treatment of sex hormone-related disorders. It has also been used for the treatment of menopausal hot flushes. Fezolinetant was optimized for use in women's health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids. Fexolinetant allows modulation of the hypothalamic-pituitary gonadal axis with a selective action on hormones relevant to disease. The agent is expected to have greater tolerability than competing products which target GnRH (Gonadotropin-releasing hormone).

纯度：≥98%

CAS：1629229-37-3